Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results
August 13, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of MedicineJoined Russell 3000 IndexStrong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK,...
Fennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Authorization
August 07, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee...
Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine
June 21, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing lossNo evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec...
Fennec Pharmaceuticals Set to Join Russell 3000 Index
June 11, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., June 11, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Announces Results of Annual Meeting
June 08, 2018 07:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., June 08, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
May 14, 2018 06:00 ET
|
Fennec Pharmaceuticals Inc.
PEDMARKTM granted Breakthrough Therapy and Fast Track Designations by FDAActively preparing for NDA submission later this yearStrong financial position with $26.7 million in cash and no debt RESEARCH...
Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™
March 27, 2018 06:30 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
March 26, 2018 06:30 ET
|
Fennec Pharmaceuticals Inc.
Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033)NASDAQ listing in September 2017Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt ...
Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK
March 21, 2018 06:30 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., March 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
Fennec Announces Closing of Public Offering
December 12, 2017 16:01 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a biotechnology company focused on the development of PEDMARK™ (a unique...